成都治血管炎医院成都治腿部静脉曲张费用多少,成都雷诺氏症治疗得多少钱,成都看静脉曲张多少钱,成都治疗海绵状血管瘤看什么科,成都治疗静脉曲张大概要花多少钱,成都脉管炎临床治疗,成都市较有名精索静脉曲张医院

The entertainment world is still reeling from the loss of Chadwick Boseman, who died on Friday at the age of 43. Boseman had reportedly been privately fighting colon cancer since 2016, meaning some of his most iconic roles — including those in films like Black Panther, Marshall and 21 Bridges — were likely filmed between grueling chemo treatments.In the face of such an insurmountable loss, doctors and medical professionals hope that Boseman's cancer battle can shine a light on the dangers of colon cancer in young and middle-aged people and encourage them to undergo annual screenings.According to the Centers for Disease Control and Prevention, colon cancer is currently the second-leading cause of cancer deaths in the United States. In 2017, more than 50,000 people died of the disease.And while colon cancer is most common in people 50 years and older, researchers say cases among younger people are on the rise.Researchers say that doctors have been able to catch the disease early in older people because of a push for increased screenings, but they're still at a loss for why the disease is increasing in young people — though rising rates of obesity may be a factor.Furthermore, Boseman's death is highlighting the rates of colon cancer in Black Americans — according to the American Cancer Society, Black people have the highest rates of colorectal cancer of any racial or ethnic group in the U.S.But what are the symptoms of the disease?According to the American Cancer Society, colon cancer typically presents with:Change of bowel habitsFeeling the need to go, but not feeling relief afterRectal bleeding with bright red bloodBlood in the stool making it look dark brown or blackCramping or abdominal painWeakness or fatigueUnintended weight lossWhile those symptoms don't necessarily guarantee a cancer diagnosis, the American Cancer Society recommends anyone with those symptoms visit a doctor.The Mayo Clinic adds that the following could leave a person with a higher risk of colon cancer:Old age (50 and above)Race factors (Black men are 24% more likely to develop colon cancer than white men, and Black men die 47% more likely to die of the disease than white men)History of colon tumors or polypsInflammatory intestinal conditions, like ulcerative colitis or Chron's diseaseFamily history of colon cancerA diet low in fiber and high in fatSedentary lifestyleDiabetesObesitySmoking/alcohol useHistory of radiation treatments in the abdomen 2468

The Food and Drug Administration says it is re-examining the safety of a medication that was approved despite concerns that not enough was known about the drug's risks.In response to questioning at a budget hearing last week, FDA Commissioner Scott Gottlieb told members of Congress that he would "take another look" at Nuplazid, which is the only drug approved to treat hallucinations and delusions associated with Parkinson's disease psychosis.The medication has been cited as a so-called "suspect" medication in hundreds of deaths voluntarily reported by caregivers, doctors and other medical professionals since it hit the market, as highlighted in a recent CNN report.The FDA told CNN this week that the agency had already begun conducting a new evaluation of the medication when Gottlieb was questioned about it at the hearing. The agency said the review had started several weeks ago."What does it take for a drug like this to be taken off the market?" asked US Rep. Rosa DeLauro, a member and former chair of the congressional subcommittee responsible for funding and overseeing the FDA.DeLauro pressed Gottlieb for answers on his agency's response to the safety concerns surrounding Nuplazid."How many more adverse events do we have to have reported? How many people, quite frankly, have to die? Why does the industry always take precedence over public health and safety?"Tracked by the FDA, the adverse event reports cited by DeLauro do not mean that a suspected medication has been ruled the cause of harm and are typically not the result of official investigations. But the FDA uses the information to monitor potential issues with a drug and can take action as needed: updating a medication's label, for instance, or restricting its use. In rare cases, the agency can even pull a drug off the market.When asked by CNN about what prompted the FDA's new evaluation of Nuplazid, the agency said the decision was based on a number of factors but wouldn't say what those factors were. Instead, it would only comment generally, saying that it identifies "potential signals of serious risk/new safety information" in part by using adverse event data and that the agency is not suggesting physicians stop prescribing the drug or take patients off of it while a safety evaluation is taking place.The FDA has noted that the death reports citing Nuplazid have typically involved elderly patients with advanced-stage Parkinson's disease who suffered from numerous medical conditions and often take other medications that can increase the risk of death.But physicians, researchers and other medical experts told CNN that the high number of reports deserved a closer look to determine whether they were related to the drug. They also recommended further testing of Nuplazid, worrying that the drug had been approved too quickly, based on too little evidence that it was safe or effective.Nuplazid's review was expedited by the FDA because it had been designated a "breakthrough therapy," meaning it demonstrated "substantial improvement" in patients with serious or life-threatening diseases compared to treatments already on the market.Dr. Paul Andreason, the physician who led the FDA's medical review of Nuplazid, warned that patients taking the drug during the company's clinical trials experienced serious outcomes, including death, at more than double the rate of those taking the placebo. But the FDA ruled that the potential benefits outweighed the risks, agreeing with an advisory committee that cited a lack of safe alternatives and the pleas from family members who claimed the drug was already helping or could help their loved ones.At that advisory committee meeting two years ago, one woman said that her grandmother had been part of the clinical trials for the drug and that Nuplazid had been life-changing."We didn't know what to expect or even if she was on the drug" or a placebo, said Zoey Wade. "We soon realized that she must be taking the drug, because she really returned to herself. Her hallucinations reduced, and she better understood what was real and what was imaginary."Shortly after Nuplazid's release, however, patients' family members, doctors and other health care professionals started reporting "adverse events" possibly linked to the medication -- including deaths, life-threatening incidents, falls, insomnia, nausea and fatigue.During the first 10 months Nuplazid was on the market, 244 deaths were reported to the FDA in which Nuplazid was a "suspect" medication, according to an analysis conducted by the Institute for Safe Medication Practices. FDA data now show that the number of reported deaths has risen to more than 700. In more than 1,000 reports, patients continued to experience hallucinations while on Nuplazid.After CNN published its investigation on Nuplazid, reporters were contacted by family members who said the drug helped tame hallucinations with few apparent side effects and others who said they believe Nuplazid contributed to their family member's decline or death. Some said they had not yet reported these experiences to the drugmaker or the FDA.While the FDA has long been criticized for being too slow to approve drugs, DeLauro seized on its push to streamline the process, lambasting the agency for putting industry interests and efficiency above public health and safety.DeLauro described the number of adverse events and deaths as "staggering" and "unprecedented." She also expressed concern that the drugmaker, Acadia Pharmaceuticals, is attempting to get the drug approved for a larger population: patients who suffer from dementia-related psychosis."I don't know why it should stay on the market, especially when the FDA has not determined it to be safe and while the number of adverse events continues to soar," she told Gottlieb.In response to the congresswoman's remarks, Acadia told CNN that adverse event data alone are "not a comprehensive and accurate indicator of the safety profile of any drug." In response to CNN's earlier report on the drug, Acadia said there are a number of reasons for the higher volume of death reports, including the fact that the company distributes Nuplazid through a network of specialty pharmacies that puts the company in more frequent contact with both patients and caregivers -- meaning Acadia is more likely to receive reports of death, which it is required to pass along to the FDA.Commissioner Gottlieb told the committee that the FDA is careful about the decisions it makes and that there may be a higher tolerance for risk in situations where there is an unmet medical need, "so long as the patient is properly informed of what those risks are." This echoed what he told CNN's Dr. Sanjay Gupta in an interview earlier this month.The FDA previously told CNN that it was aware of Nuplazid's "complex safety profile" at the time of approval and required the drugmaker to place warnings on its labeling. The agency also said that, though it was continuing to monitor available information about Nuplazid, it had "not identified a specific safety issue" not already reflected on the medication's label.DeLauro's office told CNN that it plans to follow up with the FDA about its inquiry into Nuplazid. 7224

The gluttony known as the Nathan’s Famous Hot Dog Eating Contest will go on this Saturday, but like many events being held this year, will not feature a live audience.While the event will be held at a private location in NYC, it’s unclear if all of the competitors will be able to make it.Last week, New York began requiring visitors from states with large numbers of COVID-19 cases to self-quarantine for 14 days.For perennial champion Joey Chestnut, he was fortunate to arrive in NYC in time not to be required to quarantine. Chestnut is coming into the 2020 competition after consuming 71 hot dogs in 10 minutes during the 2019 event. His 2019 performance was just shy of his record of 74 hot dogs set in 2018.“I arrived to NYC early because of risk of visitors to NY needing quarantine, my last practices were scrapped. Staying positive and focused on the 4th,” Chestnut said.The competition will air live on ESPN starting at noon on Saturday.“We’re ecstatic to make the announcement that the Hot Dog-Eating Contest will take place this year,” states James Walker, Nathan’s Famous Senior Vice President, Restaurants. “2020 has been a year for the history books, and the realization that this storied July 4th tradition would be able to occur, is a great feeling. With that being said, our country and our world has endured so much in the last couple of months, that we’d be remiss if we didn’t use this moment to honor those that have done so much for each of us during this time.” 1493

The FBI said on Tuesday that cybercriminals and foreign actors are attempting to influence the upcoming election.According to the FBI, “Foreign actors and cybercriminals could create new websites, change existing websites, and create or share corresponding social media content to spread false information in an attempt to discredit the electoral process and undermine confidence in U.S. democratic institutions.”Beyond attempts to influence the vote, the FBI says these actors are attempting to sow distrust in the electoral system. The FBI in particular warns that cybercriminals could take advantage of the likelihood several states will need additional time to count ballots due to increased mail-in voting and social distancing protocols. While a delay in results does not indicate any wrongdoing, the FBI warns that foreign actors could attempt to spread misinformation to cause distrust in the system while votes are being tallied.Last month, the Office of the Director of National Intelligence released a statement outlining efforts by Iran, China and Russia to attempt to undermine this year’s presidential election.“Ahead of the 2020 U.S. elections, foreign states will continue to use covert and overt influence measures in their attempts to sway U.S. voters’ preferences and perspectives, shift U.S. policies, increase discord in the United States, and undermine the American people’s confidence in our democratic process,” William Evanina, director of the United States National Counterintelligence and Security Center, said. "They may also seek to compromise our election infrastructure for a range of possible purposes, such as interfering with the voting process, stealing sensitive data, or calling into question the validity of the election results. However, it would be difficult for our adversaries to interfere with or manipulate voting results at scale.”As part of Evanina’s assessment, he said that China and Iran were attempting to seek a favorable outcome for Biden, while Russia was working to ensure a favorable outcome for Trump.“As Americans, we are all in this together; our elections should be our own,” Evanina previously said. “Foreign efforts to influence or interfere with our elections are a direct threat to the fabric of our democracy. Neutralizing these threats requires not just a whole-of-government approach, but a whole-of-nation effort.”The FBI offered the following recommendations to voters:Seek out information from trustworthy sources, such as state and local election officials; verify who produced the content; and consider their intent.Verify through multiple reliable sources any reports about problems in voting or election results, and consider searching for other reliable sources before sharing such information via social media or other avenues.For information about final election results, rely on state and local government election officials.Report potential election crimes—such as disinformation about the manner, time, or place of voting—to the FBI.If appropriate, make use of in-platform tools offered by social media companies for reporting suspicious posts that appear to be spreading false or inconsistent information about election-related problems or results. 3236

The dead gunman in the Sutherland Springs, Texas, church shooting was a former airman who was discharged from the military for bad conduct and may have been conducting target practice on his property last week, sources say.Details continue to trickle out Monday about the man police say is responsible for the worst mass shooting in Texas history.Devin Patrick Kelley, 26, was killed after the shooting, either by his own hand or by a gunshot from a local resident who engaged and chased Kelley, police say. 515